Research Analysts Set Expectations for Novartis Q4 Earnings

Novartis AG (NYSE:NVS) – Stock analysts at Zacks Research cut their Q4 2024 earnings per share estimates for shares of Novartis in a research report issued to clients and investors on Tuesday, November 12th. Zacks Research analyst E. Bagri now forecasts that the company will post earnings of $1.76 per share for the quarter, down from their prior estimate of $1.86. The consensus estimate for Novartis’ current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Novartis’ Q3 2025 earnings at $2.18 EPS, Q4 2025 earnings at $2.02 EPS, FY2025 earnings at $8.23 EPS, Q2 2026 earnings at $2.22 EPS and Q3 2026 earnings at $2.42 EPS.

A number of other equities analysts have also weighed in on the company. Jefferies Financial Group lowered Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, September 3rd. Bank of America downgraded shares of Novartis from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $135.00 to $130.00 in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Novartis in a research note on Friday, July 19th. BMO Capital Markets boosted their target price on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $121.00 price target (up previously from $119.00) on shares of Novartis in a report on Thursday, September 5th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $121.50.

Novartis Price Performance

NYSE NVS opened at $103.06 on Friday. The stock has a market capitalization of $210.65 billion, a P/E ratio of 11.93, a P/E/G ratio of 1.50 and a beta of 0.58. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11. The business’s fifty day moving average is $113.41 and its two-hundred day moving average is $109.79. Novartis has a 1 year low of $92.35 and a 1 year high of $120.92.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The company had revenue of $12.82 billion during the quarter, compared to analyst estimates of $12.62 billion. During the same period in the prior year, the business posted $1.74 EPS.

Institutional Investors Weigh In On Novartis

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Legacy Investment Solutions LLC bought a new position in Novartis during the third quarter valued at approximately $28,000. New Millennium Group LLC acquired a new stake in shares of Novartis in the 2nd quarter valued at $28,000. Clearstead Trust LLC boosted its holdings in Novartis by 73.5% in the first quarter. Clearstead Trust LLC now owns 269 shares of the company’s stock worth $26,000 after purchasing an additional 114 shares in the last quarter. Lynx Investment Advisory acquired a new position in Novartis during the second quarter worth $29,000. Finally, Industrial Alliance Investment Management Inc. bought a new position in Novartis during the second quarter valued at about $30,000. 13.12% of the stock is owned by hedge funds and other institutional investors.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.